Announcements

27 September 2021
Recruiting Section Editors-in-Chief for New Sections of Antibiotics


According to the aim and scope of the journal and the papers we are publishing, we are launching four new sections to improve our competitiveness and the strength of our editorial team. These sections are “Antibiotics in Animal Health”, “Antibiotic Therapy in Infectious Diseases”, “Antimicrobial Materials and Surfaces”, and “Antibiofilm Strategies”. We are recruiting Section Editors-in-Chief for these four sections of Antibiotics.

The main responsibilities of the Section Editors-in-Chief are as follows:

  • Supervising the quality of the papers in their section (when we have new submissions to the section);
  • Acting as, or recommending a Guest Editor for a Special Issue on a topic related to your research interests;
  • Providing any conference/society cooperation recommendations.

This position is open to experts on related aspects of antibiotics. To apply for this position, recommend potential candidates, or request further information, please contact the Antibiotics Editorial Office ([email protected]) or Managing Editor, Ms. Chole Lu ([email protected]).

Antibiotics
(ISSN 2079-6382, https://0-www-mdpi-com.brum.beds.ac.uk/journal/antibiotics) is an international, peer-reviewed, open-access journal published online by MDPI, Basel, Switzerland. The scope of Antibiotics includes, but is not limited to: pharmacodynamics, uses of antibiotics, antimicrobial stewardship, antibiotic resistance, and novel antimicrobial agents. We encourage scientists to publish their experimental and theoretical results in as much detail as possible. The journal has been indexed by the Science Citation Index Expanded (SCIE: Web of Science), Scopus, and other databases. Citations are available on PubMed; full texts are archived in PubMed Central. Antibiotics has a Journal Impact Factor of 4.639, ranking 26/92 (Q2) in the "Infectious Diseases" category, and 75/275 (Q2) in the "Pharmacology & Pharmacy" category in the Web of Science.

More News...
Back to TopTop